Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   UROLOGY JOURNAL   March-April 2019 , Volume 16 , Number 2; Page(s) 134 To 140.
 
Paper: 

Osteopontin and Angiogenic Factors as New Biomarkers of Prostate Cancer

 
DOI: 

10.22037/uj.v0i0.4282

 
Author(s):  Wisniewski Tomasz*, zyromska Agnieszka, Makarewicz Roman, zekanowska Ewa
 
* Department of Oncology and Brachytherapy, Nicolaus Copernicus University Collegium Medicum/ Radiotherapy Department of Franciszek Lukaszczyk Oncology Center, Bydgoszcz, Poland
 
Abstract: 
Purpose: The novel biomarkers that would identify patients at risk for relapse and metastatic spread are needed. The aim of this study was the evaluation of serum levels of osteopontin (OPN) and tumor endogenous angiogenic factors such as vascular– endothelial growth factor (VEGF), vascular-endothelial growth factor receptor 2 (VEGF R2), endostatin, angiostatin and thrombospondin 1, in prostate cancer (PC) patients. Material and Methods: Blood concentrations of the analyzed parameters were determined in 40 prostate cancer patients eligible for radiotherapy as well as in a control group consisting of 25 volunteers. Commercial ELISA kits were used for the analysis. Results: Significantly higher levels of OPN (101. 49 ng/mL vs 59. 88 ng/mL; P <. 001), endostatin (252. 60 ng/ mL vs. 223. 55 ng/mL; P =. 043), angiostatin (47 ng/mL vs. 13 ng/mL; P =. 047), VEGF (262. 1 pg/mL vs. 138. 0 pg/mL; P =. 056) and VEGF R2 (11188. 81 pg/mL vs. 9377. 50 pg/mL; P =. 047) were detected in PC patients compared with the control group. In PC patients we showed a positive correlation between OPN level and TNM clinical stage (R = 0. 36; P =. 02) and negative correlation between OPN level and hemoglobin concentration (R=-0. 33; P =. 04). Conclusion: The study showed higher levels of the angiogenic factors in PC patients compared with the control group and identified OPN as an indicator of the PC clinical stage as well as a decreased hemoglobin level.
 
Keyword(s): osteopontin,angiogenesis factors,prostate cancer
 
 
References: 
 
+ Click to Cite.
APA: Copy

Wisniewski, T., & zyromska, A., & Makarewicz, R., & zekanowska, E. (2019). Osteopontin and Angiogenic Factors as New Biomarkers of Prostate Cancer. UROLOGY JOURNAL, 16(2), 134-140. https://www.sid.ir/en/journal/ViewPaper.aspx?id=665754



Vancouver: Copy

Wisniewski Tomasz, zyromska Agnieszka, Makarewicz Roman, zekanowska Ewa. Osteopontin and Angiogenic Factors as New Biomarkers of Prostate Cancer. UROLOGY JOURNAL. 2019 [cited 2021May16];16(2):134-140. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=665754



IEEE: Copy

Wisniewski, T., zyromska, A., Makarewicz, R., zekanowska, E., 2019. Osteopontin and Angiogenic Factors as New Biomarkers of Prostate Cancer. UROLOGY JOURNAL, [online] 16(2), pp.134-140. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=665754.



 
  pdf-File
Yearly Visit 28
 
Latest on Blog
Enter SID Blog